Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment
Status:
Recruiting
Trial end date:
2030-07-31
Target enrollment:
Participant gender:
Summary
Many patients with CLL have a weakened immune system due to their disease. It increases their
risk of developing serious, treatment-requiring infections such as blood poisoning or
pneumonia, which in the worst case may end with fatal outcomes.
Serious infections due to CLL are responsible for one third of all deaths among CLL patients.
PreVent-ACaLL study will investigate whether a combination of two known types of cancer drugs
can reduce the risk of infection and thus mortality when given preventively to newly
diagnosed CLL patients.
A newly developed register-based computer model can predict which patients are at high risk
in order to develop infections as a result of their CLL. A preventive treatment might be
initiated before patients need chemotherapy. In this way, the cancer disease might be "reset"
so that the immune system, which is inhibited by CLL, is restored and the risk of fatal
infections is minimized.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Rigshospitalet, Denmark
Collaborators:
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Karolinska Institutet Stichting Hemato-Oncologie voor Volwassenen Nederland